サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1798977

経口抗糖尿病薬の世界市場

Oral Anti-Diabetic Drugs

出版日
ページ情報
英文 197 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
経口抗糖尿病薬の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

経口抗糖尿病薬の世界市場は2030年までに547億米ドルに達する見込み

2024年に454億米ドルと推定される経口抗糖尿病薬の世界市場は、2024～2030年の分析期間においてCAGR 3.2%で成長し、2030年には547億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるビグアナイドは、CAGR 4.1%を記録し、分析期間終了時には148億米ドルに達すると予想されます。α-グルコシダーゼ阻害剤セグメントの成長率は、分析期間中CAGR 3.4%と推定されます。

米国市場は124億米ドルと推定、中国はCAGR6.1%で成長予測

米国の経口抗糖尿病薬市場は2024年に124億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに109億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.5%と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界の経口抗糖尿病薬市場- 主要動向と促進要因のまとめ

2型糖尿病管理の複雑性に対応するため、経口抗糖尿病薬はどのように進化しているか？

経口抗糖尿病薬（OADs）は依然として2型糖尿病（T2DM）管理の要であり、血糖コントロールの改善を目的とした薬理学的介入のかなりの割合を占めています。インスリン治療は進行例や一部の早期発症例には不可欠であるが、世界中のT2DM患者の大多数は経口薬で治療を開始しています。長年にわたり、OAD市場はスルホニル尿素薬とビグアナイド薬という限られたレパートリーから、DPP-4阻害薬、SGLT2阻害薬、チアゾリジン薬、α-グルコシダーゼ阻害薬、併用療法を含む多様な薬理学的状況へと発展してきました。

ビグアナイド薬で第一選択薬であるメトホルミンは、その有効性、低コスト、良好な安全性プロファイルにより、依然として最も広く処方されているOADです。しかし、患者の多様性が増し、体重管理、心血管保護、腎臓の安全性に対するニーズが高まっていることから、ナトリウム-グルコース共輸送体2（SGLT2）阻害薬やグルカゴン様ペプチド-1受容体作動薬（GLP-1 RA、経口剤）のような新しいクラスの薬剤の使用が増加しています。これらの先進的な薬剤は、心血管イベントの抑制や糖尿病性腎症の緩徐化など、血糖コントロールにとどまらない多面的な効果をもたらし、経口抗糖尿病薬の治療目標を再定義しています。

どのような技術革新と併用戦略が治療成果を変えるのか？

OAD市場では、治療アドヒアランスの向上、錠剤負担の軽減、複数の病態経路の同時標的化を目的とした合剤（FDC）が急増しています。メトホルミンとDPP-4阻害薬（例、シタグリプチン、ビルダグリプチン）またはSGLT2阻害薬（例、ダパグリフロジン、エンパグリフロジン）の併用は、その相補的な作用機序から広く使用されています。この二重または三重のアプローチにより、空腹時および食後の血糖コントロールが可能となり、同時に体重減少や血圧低下などのその他の特典も得られます。

従来注射薬であった薬剤の経口製剤の開発は、最も重要なブレークスルーのひとつです。特に、経口セマグルチド（GLP-1受容体作動薬）の承認は、ペプチドベースの治療薬を消化管から投与することによって新たなフロンティアを開いた。この技術革新は、注射針恐怖症に対処し、より早期の病期での使用を拡大し、患者のコンプライアンスを向上させる。

継続的グルコースモニタリング（CGM）とコンパニオンデジタルヘルスプラットフォームも、より個別化された薬剤の滴定を可能にしています。製薬会社は、患者が血糖値の目標値を維持できるよう、テレヘルスやAIを活用したアドヒアランス・ツールを経口薬レジメンに統合する動きが加速しています。さらに、インスリン抵抗性、炎症、腸内細菌叢の調節を標的とした新規治療クラスの研究が拡大しており、疾患修飾の可能性を持つ次世代経口療法の見通しが立っています。

どのような患者集団と市場力学が需要とアクセスを牽引しているのか？

2型糖尿病の負担は世界的に増加しており、現在5億4,000万人以上が糖尿病を患っています。その90％がT2DM患者です。このため、特にインスリンへのアクセスが制限され、医療制度がひっ迫している低・中所得国（LMICs）では、費用対効果が高く、スケーラブルなOAD治療に対する莫大な需要が生じています。アジア太平洋、中東、ラテンアメリカでは、人口の高齢化、座りがちなライフスタイル、食生活の変化などを背景に、OADの急速な普及が見られます。

2億人以上の糖尿病患者を抱えるインドと中国では、手頃な価格で入手できるメトホルミンとスルホニル尿素が引き続き主流です。しかし、都市部では、認知度、保険の普及、治療ガイドラインの進化に伴い、新しい薬剤への移行が徐々に進んでいます。一方、米国、ドイツ、日本などの欧米市場では、支払側の支持とアウトカムベースの臨床エビデンスにより、SGLT2阻害薬やDPP-4阻害薬がファーストライン治療やセカンドライン治療に組み込まれつつあります。

高齢者、心血管系合併症を有する患者、肥満症患者は、新しいOADクラスの優先順位の高い患者層となりつつあります。SGLT2阻害薬や経口GLP-1 RAは、動脈硬化性心血管病や慢性腎臓病を有する患者で特に好まれています。かつては稀であった小児の2型糖尿病も臨床上の課題として浮上しており、経口薬が思春期の患者における安全性と有効性を評価されつつあります。

市場拡大と戦略的差別化の原動力は？

世界の経口抗糖尿病薬市場の成長は、糖尿病有病率の増加、次世代治療薬のパイプラインの拡大、早期薬理学的介入の重視の高まりなど、いくつかの要因によって牽引されています。ADA、EASD、WHOなどの新しい臨床ガイドラインに基づく治療目標の厳格化により、併用療法の早期かつ積極的な開始が奨励され、市場規模に拍車をかけています。

市場参入戦略は、コストの課題に対処するために進化しています。段階的価格設定、官民パートナーシップ、新型OADの国家必須医薬品リスト（EML）への収載などが、中南米諸国でのアクセス拡大に役立っています。各国政府は、糖尿病に関連する合併症の経済的打撃と闘うために、集団レベルのスクリーニング・プログラムや薬剤の補助金支給モデルを展開しています。さらに、ユニバーサル・ヘルス・カバレッジ（UHC）の枠組みが強化されるにつれて、先進的なOADsのフォーミュラリーへの組み入れが増加すると予想されます。

競合面では、メルク、アストラゼネカ、ベーリンガーインゲルハイム、ノボノルディスク、サノフィ、武田薬品といった製薬大手が、研究開発、ライフサイクル管理、デジタル統合に多額の投資を行っています。旧来の薬剤クラス別ではバイオシミラーとジェネリックの競合が激化しており、価格とマージンを圧迫する一方、全体的な普及を後押ししています。1日1回投与、患者にやさしいパッケージング、価値に応じた償還契約などによる差別化は、飽和市場においてますます重要になってきています。

糖尿病がマルチシステム疾患となり、経口療法の役割が血糖コントロールから臓器保護へと拡大する中、世界のOAD市場は持続的な成長を遂げる態勢を整えています。治療イノベーション、デジタルサポートツール、アクセスイニシアチブの融合が、精密性、利便性、患者中心の糖尿病治療の新時代を形成しつつあります。

セグメント

医薬品（ビグアナイド薬、α-グルコシダーゼ阻害薬、ドパミン-D2受容体作動薬、ナトリウム-グルコース共輸送体-SGLT-2阻害薬、ジペプチジルペプチダーゼ-DPP-4阻害薬、スルホニル尿素薬、メグリチニド薬）

調査対象企業の例

  • Astellas Pharma
  • AstraZeneca
  • Bayer AG
  • Biocon
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals
  • Johnson & Johnson（Janssen Pharmaceuticals）
  • Lupin Limited
  • Mankind Pharma
  • Merck & Co., Inc.（MSD）
  • Merck KGaA
  • Novartis
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi
  • Servier Laboratories
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP39141

Global Oral Anti-Diabetic Drugs Market to Reach US$54.7 Billion by 2030

The global market for Oral Anti-Diabetic Drugs estimated at US$45.4 Billion in the year 2024, is expected to reach US$54.7 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Biguanides, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$14.8 Billion by the end of the analysis period. Growth in the Alpha-glucosidase inhibitors segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.4 Billion While China is Forecast to Grow at 6.1% CAGR

The Oral Anti-Diabetic Drugs market in the U.S. is estimated at US$12.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.9 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Oral Anti-Diabetic Drugs Market - Key Trends & Drivers Summarized

How Are Oral Anti-Diabetic Drugs Evolving to Meet the Complexities of Type 2 Diabetes Management?

Oral anti-diabetic drugs (OADs) remain the cornerstone of type 2 diabetes mellitus (T2DM) management, accounting for a substantial share of pharmacological interventions aimed at improving glycemic control. While insulin therapy is indispensable for advanced and certain early-onset cases, the vast majority of T2DM patients worldwide begin treatment with oral medications. Over the years, the OAD market has evolved from a limited repertoire of sulfonylureas and biguanides to a diverse pharmacological landscape encompassing DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, and combination therapies.

Metformin, a biguanide and first-line drug, remains the most widely prescribed OAD due to its efficacy, low cost, and favorable safety profile. However, rising patient heterogeneity and the growing need for weight management, cardiovascular protection, and renal safety have led to increasing use of newer classes like sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs, in oral form). These advanced agents provide multifaceted benefits beyond glucose control, such as reducing cardiovascular events and slowing diabetic nephropathy, thus redefining the therapeutic goals of oral anti-diabetic treatments.

Which Innovations and Combination Strategies Are Transforming Therapeutic Outcomes?

The OAD market is witnessing a surge in fixed-dose combinations (FDCs), aiming to improve treatment adherence, reduce pill burden, and simultaneously target multiple pathogenic pathways. Combinations such as metformin with DPP-4 inhibitors (e.g., sitagliptin, vildagliptin) or SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) are widely used for their complementary mechanisms of action. This dual or triple approach enables both fasting and postprandial glycemic control, while offering additional benefits like weight loss and blood pressure reduction.

The development of oral formulations of traditionally injectable classes is one of the most significant breakthroughs. Notably, the approval of oral semaglutide (a GLP-1 receptor agonist) has opened new frontiers by delivering peptide-based therapy via the gastrointestinal tract-previously considered unfeasible due to enzymatic degradation. This innovation addresses needle phobia, expands usage in earlier disease stages, and enhances overall patient compliance.

Continuous glucose monitoring (CGM) and companion digital health platforms are also enabling more personalized drug titration. Pharmaceutical companies are increasingly integrating telehealth and AI-powered adherence tools with oral drug regimens to help patients stay within their glycemic targets. Moreover, research is expanding into novel therapeutic classes targeting insulin resistance, inflammation, and gut microbiota modulation-offering prospects for next-generation oral therapies with disease-modifying potential.

Which Patient Populations and Global Markets Are Driving Demand and Access Dynamics?

The burden of type 2 diabetes is rising globally, with over 540 million people currently living with diabetes-90% of whom are T2DM patients. This is creating enormous demand for cost-effective and scalable OAD therapies, particularly in low- and middle-income countries (LMICs) where insulin access is limited and health systems are strained. Asia-Pacific, the Middle East, and Latin America are witnessing rapid uptake of OADs, driven by aging populations, sedentary lifestyles, and dietary transitions.

In India and China, which together account for over 200 million diabetic individuals, metformin and sulfonylureas continue to dominate due to affordability and availability. However, urban centers are experiencing a gradual shift toward newer agents as awareness, insurance penetration, and treatment guidelines evolve. In contrast, Western markets like the U.S., Germany, and Japan have seen greater integration of SGLT2 inhibitors and DPP-4 inhibitors into first- and second-line therapy, owing to payer support and outcomes-based clinical evidence.

Elderly populations, patients with cardiovascular comorbidities, and individuals with obesity are becoming high-priority segments for newer OAD classes. SGLT2 inhibitors and oral GLP-1 RAs are particularly favored in patients with atherosclerotic cardiovascular disease or chronic kidney disease. Pediatric type 2 diabetes, once rare, is also emerging as a clinical challenge, and oral drugs are being evaluated for safety and efficacy in adolescent populations.

What Forces Are Driving Market Expansion and Strategic Differentiation?

The growth in the global oral anti-diabetic drugs market is driven by several factors, including the increasing prevalence of diabetes, expanding pipeline of next-generation therapeutics, and growing emphasis on early pharmacological intervention. Tighter treatment targets under new clinical guidelines-such as those from ADA, EASD, and WHO-are encouraging earlier and more aggressive initiation of combination therapy, fueling market volume.

Market access strategies are evolving to address cost challenges. Tiered pricing, public-private partnerships, and inclusion of newer OADs in national essential medicines lists (EMLs) are helping expand access in LMICs. Governments are rolling out population-level screening programs and subsidized drug distribution models to combat the economic toll of diabetes-related complications. Moreover, as universal health coverage (UHC) frameworks strengthen, formulary inclusion of advanced OADs is expected to rise.

On the competitive front, pharmaceutical majors like Merck, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, and Takeda are investing heavily in R&D, lifecycle management, and digital integration. Biosimilar and generic competition is intensifying in older drug classes, pressuring prices and margins while boosting overall adoption. Differentiation through once-daily dosing, patient-friendly packaging, and value-based reimbursement contracts is becoming increasingly critical in saturated markets.

With diabetes becoming a multi-system disorder and the role of oral therapies expanding from glycemic control to organ protection, the global OAD market is poised for sustained growth. The convergence of therapeutic innovation, digital support tools, and access initiatives is shaping a new era of precision, convenience, and patient-centric diabetes care.

SCOPE OF STUDY:

The report analyzes the Oral Anti-Diabetic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Astellas Pharma
  • AstraZeneca
  • Bayer AG
  • Biocon
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Lupin Limited
  • Mankind Pharma
  • Merck & Co., Inc. (MSD)
  • Merck KGaA
  • Novartis
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi
  • Servier Laboratories
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oral Anti-Diabetic Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Burden Spurs Demand for Oral Anti-Diabetic Medications
    • Shift Toward Early Pharmacological Intervention Strengthens Market Penetration
    • Launch of Combination Therapies Expands Treatment Scope for Type 2 Diabetes
    • Patient Preference for Non-Invasive Regimens Drives Adoption of Oral Formulations
    • Favorable Reimbursement Policies for Chronic Care Boost Prescription Volumes
    • Increased R&D Investment in DPP-4, SGLT2, and GLP-1 Agents Fuels Product Pipeline
    • Guideline Revisions Promoting Oral Agents as First-Line Therapy Support Uptake
    • Pharma-Biotech Collaborations Accelerate Development of Next-Gen Anti-Diabetics
    • Rising Awareness About Diabetes Self-Management Expands Demand in Emerging Markets
    • Advances in Sustained-Release Drug Technologies Improve Compliance Rates
    • Availability of Fixed-Dose Combinations Drives Treatment Simplification
    • Efforts to Reduce Insulin Dependence Among Type 2 Patients Strengthen Market Opportunity
    • Increasing Distribution via E-Pharmacies and Chronic Care Platforms Enhances Accessibility
    • Growing Lifestyle-Related Diabetes Incidence Promotes Preventive Oral Drug Use
    • Shift Toward Personalized Diabetes Therapies Spurs Precision Medicine Applications
    • Entry of Generic Players Post Patent Expiry Enhances Market Affordability
    • Clinical Studies on Cardiovascular and Renal Benefits Reinforce Prescriber Confidence
    • Regulatory Focus on Risk Mitigation Encourages Safer Drug Innovations
    • Rising Procurement by Public Health Programs Supports Volume-Based Expansion
    • Focus on Health Equity Drives Penetration in Underserved Regions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oral Anti-Diabetic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oral Anti-Diabetic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oral Anti-Diabetic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Alpha-glucosidase inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Alpha-glucosidase inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Alpha-glucosidase inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dopamine -D2 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dopamine -D2 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Dopamine -D2 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sodium-glucose Cotransport -SGLT-2 inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sodium-glucose Cotransport -SGLT-2 inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Sodium-glucose Cotransport -SGLT-2 inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dipeptidyl Peptidase - DPP-4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dipeptidyl Peptidase - DPP-4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dipeptidyl Peptidase - DPP-4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Meglitinides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Meglitinides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Meglitinides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • JAPAN
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • CHINA
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • EUROPE
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Oral Anti-Diabetic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Oral Anti-Diabetic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • FRANCE
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: France 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • GERMANY
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Germany 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Italy 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: UK 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Spain 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Russia 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Rest of Europe 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Oral Anti-Diabetic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Oral Anti-Diabetic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Asia-Pacific 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 71: Australia Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Australia 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • INDIA
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: India 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: South Korea 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Oral Anti-Diabetic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Oral Anti-Diabetic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Latin America 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 89: Argentina Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Argentina Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Argentina 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 92: Brazil Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Brazil Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Brazil 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 95: Mexico Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Mexico Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Mexico 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Latin America Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Latin America 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Oral Anti-Diabetic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Oral Anti-Diabetic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Middle East 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 107: Iran Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Iran Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Iran 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 110: Israel Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Israel Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Israel 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Saudi Arabia Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Saudi Arabia 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 116: UAE Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UAE Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UAE 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Middle East Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Middle East 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030
  • AFRICA
    • Oral Anti-Diabetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 122: Africa Recent Past, Current & Future Analysis for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Africa Historic Review for Oral Anti-Diabetic Drugs by Drugs - Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Africa 16-Year Perspective for Oral Anti-Diabetic Drugs by Drugs - Percentage Breakdown of Value Sales for Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -SGLT-2 inhibitor, Dipeptidyl Peptidase - DPP-4 Inhibitors, Sulfonylureas and Meglitinides for the Years 2014, 2025 & 2030

IV. COMPETITION